K562 AZQR Cell Line

Catalogue number: 153252 Sub-type: Continuous Images:

Contributor

Inventor: Timothy Ward Institute: Cancer Research UK Manchester Institute Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: K562 AZQR Cell Line

Alternate name:

Class:

Conjugate:

Cancer Tools.org Description: The cells have been shown to contain decreased levels of glutathione and superoxoid dismutase. They are cross-resistant to adriamycin, mitzolamide, MMNG and mitmycin. Cells should be challenged with AZQ at every 4th passage at a minimum density of 100,000 cells/ml. It is recommended to cultivate the cells without drug on resuscitation.

Purpose: Parental cell: K562 **Organism:** Human **Tissue:** Lymphatic Tissue Model: Tumour line Gender: **Isotype: Reactivity:** Selectivity: Host: Immunogen: Immunogen UNIPROT ID: Sequence: Growth properties: Suspension Production details: The drug resistant cell line K562 AZQ was developed from the parent K562 cell line by treatment with AZQ C215-bis (carboethoxyamino)-3, 6-diazitinyl 1;4 (benzoquinone). Formulation:

Recommended controls:

Bacterial resistance: Selectable markers: Additional notes:

Target details

Target:

Target alternate names:

Target background:

Molecular weight:

Ic50:

Applications

Application: Application notes:

Handling

CancerTools.org Format: Frozen **Concentration:** Passage number: Growth medium: Subculture Routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37??°C.Culture Medium: RPMI 1640 + 10% Foetal Bovine Serum (FBS) + 2mM Glutamine. Challenge with 1 mM AZQ every 4th passage. Temperature: Atmosphere: Volume: Storage medium: Storage buffer:

Storage conditions: Shipping conditions: Dry ice

Related tools

Related tools:

References

References: Burns et al. 1994. Br J Cancer. 70(4):591-5. PMID: 7917902. ; The p53 status of cultured human premalignant oral keratinocytes. ; Chang et al. 1992. Int J Cancer. 52(6):896-902. PMID: 1459732. ; DOK, a cell line established from human dysplastic oral mucosa, shows a partially transformed non-malignant phenotype.

Cancer Tools.org